New Applications of Heparin and Other Glycosaminoglycans
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
dARK ID: | ark:/48912/001300000vfm1 |
DOI: | 10.3390/molecules22050749 |
Texto Completo: | http://dx.doi.org/10.3390/molecules22050749 https://repositorio.unifesp.br/handle/11600/54540 |
Resumo: | Heparin, the widely used pharmaceutical anticoagulant, has been in clinical use for well over half a century. Its introduction reduced clotting risks substantially and subsequent developments, including the introduction of low-molecular-weight heparin, made possible many major surgical interventions that today make heparin an indispensable drug. There has been a recent burgeoning of interest in heparin and related glycosaminoglycan (GAG) polysaccharides, such as chondroitin sulfates, heparan sulfate, and hyaluronate, as potential agents in various applications. This ability arises mainly from the ability of GAGs to interact with, and alter the activity of, a wide range of proteins. Here, we review new developments (since 2010) in the application of heparin and related GAGs across diverse fields ranging from thrombosis and neurodegenerative disorders to microbiology and biotechnology. |
id |
UFSP_d4f1827169c5f76e8f13d774d9380d2c |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/54540 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
New Applications of Heparin and Other Glycosaminoglycansheparinglycosaminoglycanschondroitin sulfateHeparin, the widely used pharmaceutical anticoagulant, has been in clinical use for well over half a century. Its introduction reduced clotting risks substantially and subsequent developments, including the introduction of low-molecular-weight heparin, made possible many major surgical interventions that today make heparin an indispensable drug. There has been a recent burgeoning of interest in heparin and related glycosaminoglycan (GAG) polysaccharides, such as chondroitin sulfates, heparan sulfate, and hyaluronate, as potential agents in various applications. This ability arises mainly from the ability of GAGs to interact with, and alter the activity of, a wide range of proteins. Here, we review new developments (since 2010) in the application of heparin and related GAGs across diverse fields ranging from thrombosis and neurodegenerative disorders to microbiology and biotechnology.Fed Univ Sao Paulo UNIFESP, Dept Biochem, BR-04044020 Sao Paulo, SP, BrazilUniv Liverpool, Inst Integrat Biol, Dept Biochem, Crown St, Liverpool L69 7ZB, Merseyside, EnglandNatl Inst Biol Stand & Controls, Blanche Lane, Potters Bar EN6 3QG, Herts, EnglandFed Univ Sao Paulo UNIFESP, Dept Biochem, BR-04044020 Sao Paulo, SP, BrazilWeb of ScienceMdpi Ag2020-07-13T11:53:19Z2020-07-13T11:53:19Z2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion-http://dx.doi.org/10.3390/molecules22050749Molecules. Basel, v. 22, n. 5, p. -, 2017.10.3390/molecules22050749WOS000404522900072.pdf1420-3049https://repositorio.unifesp.br/handle/11600/54540WOS:000404522900072ark:/48912/001300000vfm1engMoleculesBaselinfo:eu-repo/semantics/openAccessLima, Marcelo [UNIFESP]Rudd, TimothyYates, Edwin [UNIFESP]reponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2021-09-29T14:54:12Zoai:repositorio.unifesp.br/:11600/54540Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-12-11T20:39:25.132067Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
New Applications of Heparin and Other Glycosaminoglycans |
title |
New Applications of Heparin and Other Glycosaminoglycans |
spellingShingle |
New Applications of Heparin and Other Glycosaminoglycans New Applications of Heparin and Other Glycosaminoglycans Lima, Marcelo [UNIFESP] heparin glycosaminoglycans chondroitin sulfate Lima, Marcelo [UNIFESP] heparin glycosaminoglycans chondroitin sulfate |
title_short |
New Applications of Heparin and Other Glycosaminoglycans |
title_full |
New Applications of Heparin and Other Glycosaminoglycans |
title_fullStr |
New Applications of Heparin and Other Glycosaminoglycans New Applications of Heparin and Other Glycosaminoglycans |
title_full_unstemmed |
New Applications of Heparin and Other Glycosaminoglycans New Applications of Heparin and Other Glycosaminoglycans |
title_sort |
New Applications of Heparin and Other Glycosaminoglycans |
author |
Lima, Marcelo [UNIFESP] |
author_facet |
Lima, Marcelo [UNIFESP] Lima, Marcelo [UNIFESP] Rudd, Timothy Yates, Edwin [UNIFESP] Rudd, Timothy Yates, Edwin [UNIFESP] |
author_role |
author |
author2 |
Rudd, Timothy Yates, Edwin [UNIFESP] |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Lima, Marcelo [UNIFESP] Rudd, Timothy Yates, Edwin [UNIFESP] |
dc.subject.por.fl_str_mv |
heparin glycosaminoglycans chondroitin sulfate |
topic |
heparin glycosaminoglycans chondroitin sulfate |
description |
Heparin, the widely used pharmaceutical anticoagulant, has been in clinical use for well over half a century. Its introduction reduced clotting risks substantially and subsequent developments, including the introduction of low-molecular-weight heparin, made possible many major surgical interventions that today make heparin an indispensable drug. There has been a recent burgeoning of interest in heparin and related glycosaminoglycan (GAG) polysaccharides, such as chondroitin sulfates, heparan sulfate, and hyaluronate, as potential agents in various applications. This ability arises mainly from the ability of GAGs to interact with, and alter the activity of, a wide range of proteins. Here, we review new developments (since 2010) in the application of heparin and related GAGs across diverse fields ranging from thrombosis and neurodegenerative disorders to microbiology and biotechnology. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017 2020-07-13T11:53:19Z 2020-07-13T11:53:19Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.3390/molecules22050749 Molecules. Basel, v. 22, n. 5, p. -, 2017. 10.3390/molecules22050749 WOS000404522900072.pdf 1420-3049 https://repositorio.unifesp.br/handle/11600/54540 WOS:000404522900072 |
dc.identifier.dark.fl_str_mv |
ark:/48912/001300000vfm1 |
url |
http://dx.doi.org/10.3390/molecules22050749 https://repositorio.unifesp.br/handle/11600/54540 |
identifier_str_mv |
Molecules. Basel, v. 22, n. 5, p. -, 2017. 10.3390/molecules22050749 WOS000404522900072.pdf 1420-3049 WOS:000404522900072 ark:/48912/001300000vfm1 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Molecules |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
- |
dc.coverage.none.fl_str_mv |
Basel |
dc.publisher.none.fl_str_mv |
Mdpi Ag |
publisher.none.fl_str_mv |
Mdpi Ag |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1822251013463080960 |
dc.identifier.doi.none.fl_str_mv |
10.3390/molecules22050749 |